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A Successfully Treated Case of Recurrent Focal Segmental 
Glomerulosclerosis (FSGS) with Plasmapheresis and High 
dose Methylprednisolone Pulse Therapy
Focal segmental glomerulosclerosis (FSGS) in children, which is a kind of nephrotic 
syndrome showing steroid resistance, usually progresses to a substantial number 
of end stage renal disease (ESRD). Although the pathogenesis of primary FSGS is 
unclear, several recent studies have reported that FSGS is associated with circu-
lating immune factors such as soluble urokinase-type plasminogen activator re-
ceptor (suPAR) or anti-CD40 autoantibody. We report a successfully treated case 
of a 19-year-old female patient who experienced a recurrence of primary FSGS. 
After the diagnosis of FSGS, the patient progressed to ESRD and received a  kidney 
trans plantation (KT). Three days later, recurrence was suspected through prote-
inuria and hypoalbuminemia. She has been performed plasmapheresis and high 
dose methylprednisolone pulse therapy and shown remission status without 
increasing proteinuria for four years after KT. In conclusion, strong immunosup-
pressive the rapy may be helpful for a good prognosis of recurrent FSGS, suppres-
sing several immunologic circulating factors related disease pathogenesis. 
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Introduction
Idiopathic nephrotic syndrome is the most common glomerular disease in 
children. Also, congenital anomalies of the kidney and urinary tract are the 
most common cause of end-stage renal disease (ESRD) in children, followed 
by focal segmental glomerulosclerosis (FSGS) that is a kind of intractable glo-
merular disease1). FSGS is one of the steroid resistant nephrotic syndromes 
and accounts for about 20% of children with nephrotic syndrome and about 
50% of them progress to ESRD2,3).
According to reports of the causes of FSGS, the main cause of primary 
FSGS is thought to be a podocyte injury by several circulating factors. The 
proposed caused of secondary FSGS are genetic, virus infections (e.g., human 
immunodeficiency virus type 1, parvovirus B19, simian virus 40, cytomegalo-
virus, Epstein-Barr virus), drugs (e.g., heroin, interferons alfa, beta, and gam-
ma, lithium, pamid ronate, sirolimus, calcineurin-inhibitor nephrotoxicity, 
anabolic steroids) and adaptive (reduced renal mass and renal hypertension)2). 
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Steroid resistant FSGS in children usually gradually pro-
gresses to ESRD and needs to be re ceived renal replacement 
therapies such as dialysis or kidney transplantation (KT). 
Even the patient has been performed KT recurrence rate is 
about 20-50%4).
Although the pathological mechanism of recurrent FSGS 
has not yet been elucidated, previous studies have reported 
that proteinuria occurs when injected into rats with serum 
from FSGS patients5). Recently, it has been reported that 
increased soluble urokinase-type plasminogen activator 
receptor (suPAR) affects the pathogenesis of kidney disease, 
especially FSGS6). In addition, there are studies that anti-
CD40 autoantibody may be a potential circulating factor 
related to FSGS disease pathogenesis7,8). 
This report describes a case of successful treatment with 
plasmapheresis and high dose immunotherapy to strongly 
control immunologic circulating factors in recurrent FSGS 
patients after KT. 
Case report 
A 2-year-old female was diagnosed with nephrotic synd-
rome in February 2000 and had no family history. The pa-
tient was treated with deflazacort, but edema and protei-
nuria were repeatedly relapsed. Renal biopsy was per formed 
in November 2000 for further evaluation of recurrence and 
minimal change disease was diagnosed. After that, methyl-
prednisolone (MP) pulse therapy was performed and cyc-
losporine was added, but proteinuria, facial edema, hypoal-
buminemia did not be improved con tinuously. Therefore, 
a second renal biopsy was performed in October 2001 for 
evaluation and FSGS was finally diagnosed.
After FSGS diagnosis, 6 cycles of MP pulse therapy (30 
mg/kg) and 6 cycles of cytoxan pulse therapy (500 mg/BSA) 
were performed (from November 2001 to April 2002), and 
deflazacort and cyclosporine were maintained. However, 
relapses were repeated even though mycophenolate mofetil 
was added from September 2005 and eventually the disease 
progressed to ESRD. Eventually, at the age of 15, she received 
bilateral nephrectomy and living related donor KT in Feb-
ruary 2013. The allograft functioned well imme diately after 
reperfusion, but symptoms of nephrotic synd rome such as 
massive proteinuria exceeding 14 g/d, hypoal buminemia 
(serum albumin 2.2 g/dL) and hypercholesterolemia (cho-
lesterol 247 mg/dL) appeared on day 3 after KT. Three 
courses of plasmapheresis were tried at first, but they were 
ineffective. So the patient received a drug regimen with in-
fusions of 20 mg/kg MP pulse therapy for 3 conse cutive 
days every two weeks until 6 months after transplan tation. 
After 6th infusion of pulse therapy, a graft function rapidly 
recovered and immediate reduction of serum crea tinine 
and proteinuria was appeared. The patient achieved com-
plete remission of proteinuria with stable renal func tion 
within 4 months of beginning of treatment. Four years after 
transplantation, no signs of FSGS recurrence are evi dent 
and graft function remains good (Fig. 1). Currently, the 
patient maintains taking immunosuppressants (tacrolimus, 
prednisolone, and mycophenolate) for preventing trans-
plant rejection. 
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Fig. 1. Clinical course of treatment to the patient with FSGS showing recurrence after receiving KT 
Fig. 1. Clinical course of treatment to the patient  with recurrence of 3 days after receiving KT. FSGS, focal 
segmental glomerulosclerosis; KT, kidney transplantation; MP, methylprednisolone.
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Discussion
The recurrence rate of primary FSGS after KT is relatively 
high, reported from 20 to 50% of patients4). It is known that 
two kinds of presentations can be came out after KT: an 
early recurrence and a late recurrence. Early recurrence can 
be frequently developed in about 10-18 days after KT, cha-
racterized by a nephrotic range of proteinuria with develop-
ment of histological lesions of the new kidney9). In contrast, 
patients with a late recurrence shows massive proteinuria 
within several months or years after KT9). The graft survival 
is poor in children with recurrence of FSGS after KT be-
cause reported the median survival is only 5 months10). The 
risk of graft failure is higher in children with an early re-
currence than a late one11). 
Despite the high incidence of recurrence and graft failure 
of FSGS after KT, however, the pathogenesis of recurrent 
FSGS is not well established from now on. In recent studies, 
several circulating factors have been suggested as a key role 
in the disease mechanism of FSGS7,12). Several circulating 
factors which have been proposed are as follows: (1) suPAR 
and (2) anti-CD40 autoantibody.
SuPAR is released from the component of uPAR, which 
is the receptor of urokinase-type plasminogen activator 
(uPA) system13). In 2011, Wei et al. firstly reported that FSGS 
patients have two-thirds of elevated levels of suPAR and 
suggested that circulating suPAR could be a predictive 
value of FSGS recurrence in KT14). They hypothesized that 
suPAR enters the kidney glomerulus and activates β3 inte-
grin, which is the major anchoring proteins in glomerular 
basement membrane of podocyte14). Thus, podocyte dys-
function and effacement of membrane are developed re-
sulting proteinuria14). There have been controversies, how-
ever, that suPAR levels can be increased not only in FSGS 
but also in other glomerular diseases or other systematic 
dis eases such as paroxysmal nocturnal hemoglobinuria, 
in fectious diseases including Human Immunodeficiency 
Virus (HIV)-1, tuberculosis sepsis, and malignancies13,15). In 
addition, high-serum suPAR can show inverse correlation 
with estimated glomerular filtration rate (GFR)16). 
Anti-CD40 autoantibody is also known as a circulating 
factor as an additional therapeutic target which cooperates 
with circulating suPAR with developing podocyte injury 
and proteinuria8). In animal models, injecting anti-CD40 
autoantibody developed FSGS and some cases improved by 
manipulation of humoral response with plasmapheresis and 
rituximab17,18). Besides, there is a report that recurred FSGS 
after KT was cured by plasma pheresis and rituxi mab19).
In our case, the patient showed massive proteinuria within 
three days after KT suggesting an early recurrence of FSGS. 
She has a high risk of graft failure, so we performed plas-
mapheresis and high-dose methylprednisolone protocol 
to reduce circulating factors. These treatment was effective 
because she shows maintainance of remission status without 
increasing proteinuria for three years after KT. This case 
suggests that the pathogenesis of recurrence can be related 
to immune mechanisms and serological dysregulation due 
to circulating factors. Also, high-dose methylprednisolone 
pulse therapy may have threshold dose of inducing remis-
sion. In other words, if immunesuppressants are not enough 
to suppress these relating circulating factors, the disease 
can relapse more often.
 In conclusion, we should consider strong immunosup-
pressive therapy as soon as the patient with FSGS showing 
recurrence before proceeding to ESRD. The good response 
to the high-dose methylprednisolone combined plasma-
pheresis may suggest the autoimmune nature of FSGS re-
lating immunologic circulating factors.  
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